Omecamtiv Mecarbil: A Personalized Treatment for Patients With Severely Impaired Ejection Fraction
- PMID: 34015476
- DOI: 10.1016/j.jacc.2021.04.077
Omecamtiv Mecarbil: A Personalized Treatment for Patients With Severely Impaired Ejection Fraction
Keywords: cardiovascular outcomes trial; heart failure with reduced ejection fraction; myotrope.
Conflict of interest statement
Funding Support and Author Disclosures Dr. Ferreira serves as a consultant for Boehringer Ingelheim.
Comment on
-
Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF.J Am Coll Cardiol. 2021 Jul 13;78(2):97-108. doi: 10.1016/j.jacc.2021.04.065. Epub 2021 May 17. J Am Coll Cardiol. 2021. PMID: 34015475 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources